✦ LIBER ✦

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

✍ Scribed by A Mukhopadhyay; N Curtin; R Plummer; RJ Edmondson

Book ID: 111163248
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 72 KB
Volume: 118
Category: Article
ISSN: 1470-0328
DOI: 10.1111/j.1471-0528.2010.02838.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinicopathological Features of Homologo

Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

✍ Mukhopadhyay, A.; Plummer, E. R.; Elattar, A.; Soohoo, S.; Uzir, B.; Quinn, J. E 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 388 KB

[Advances in Predictive, Preventive and

[Advances in Predictive, Preventive and Personalised Medicine] New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM Volume 3 || Cancer Predisposition in Diabetic Patients: Risk Assessment and Targeted Preventive Measures

✍ Mozaffari, Mahmood S. 📂 Article 📅 2013 🏛 Springer Netherlands ⚖ 860 KB

Low drug resistance to both platinum and

Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer

✍ Koji Matsuo; Virginia K. Bond; Michele L. Eno; Dwight D. Im; Neil B. Rosenshein 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract The objective of this study was to evaluate the role of an __in vitro__ drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer. All patients with FIGO Stage IIIc and IV who received postoperative chemotherap